March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London
March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the unknown causes of preterm birth and new ways to prevent it.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180306006632/en/
This March of Dimes Prematurity Research Center at Imperial College London is supported by a grant from Ferring Pharmaceuticals. Both Ferring and March of Dimes are committed to advancing research to help prevent the 15 million preterm births each year worldwide. Preterm birth is responsible for 1.1 million infant deaths each year.1
“We’re delighted that the talented scientists at Imperial College London will join as the sixth March of Dimes Prematurity Research Center to help us get closer to a world in which all babies are born healthy,” said Stacey D. Stewart, president of March of Dimes. “It’s vital that our team is able to share information and findings with colleagues outside of the U.S., in order to accelerate the discovery of solutions to the serious problem of premature birth.”
“Globally, too many babies are being born too soon, and too many families are suffering the consequences,” said Per Falk, Executive Vice President and Chief Science Officer, Ferring Pharmaceuticals. “Ferring is committed to addressing unmet patient needs in reproductive medicine and women’s health, including the growing rates of preterm birth worldwide. We believe that this new center will accelerate the development of new healthcare solutions that are urgently needed to help babies that are born earlier than expected.”
Phillip Bennett, Professor of Obstetrics and Gynaecology at Imperial College London, and the principal investigator of the new Center, said, “We are proud to have been selected to join the March of Dimes Prematurity Research Center family. Imperial College London and its partner hospitals have renowned clinics for supporting women who deliver preterm, as well as a long tradition of ground-breaking research in this area. As London is a truly global city, we are also fortunate to encompass a large and diverse patient population.”
“Our teams of world-class scientists will be using the latest technologies, some unique to Imperial, to study how the body recognises and interacts with bacteria and other microbes in the birth canal. This will enable us to develop methods for predicting--and ultimately preventing--preterm birth.”
The March of Dimes European Prematurity Research Center at Imperial College London will be a partnership between the College and three major London hospitals: Queen Charlotte’s and Chelsea, St. Mary’s Hospital, and Chelsea and Westminster. Each of these hospitals deliver around 5,000 babies a year.
The network of March of Dimes Prematurity Research Centers encompasses approximately 200 scientists in numerous fields, including obstetrics, neonatology, genetics and genomics, immunology, engineering, informatics, and social sciences. (NOTE: See below for a complete list of the Prematurity Research Centers).
Each March of Dimes Prematurity Research Center is assigned a theme or research target. The theme selected for Imperial College London is entitled, “Microbe-Host Interactions.” This team of scientists will identify and characterise these complex processes in order to obtain insight into why some women are at higher risk for preterm birth.
About Preterm Birth
Preterm birth (before 37 weeks of pregnancy) and its consequences are the leading cause of death among children under age five worldwide. Babies who survive an early birth often face lifelong health challenges, such as breathing problems, cerebral palsy, and learning disabilities. The preterm birth rate is on the rise in the United States, climbing for a second year in a row in 2016.
Quick viewable link for B-roll footage on preterm birth: https://www.youtube.com/watch?v=FbFhPnJy3B0
To download B-roll footage on preterm birth: http://bit.ly/2GUyWMsMOD-Imperial-broll
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.
Imperial is the UK's most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry.
About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every family can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we stand up for every mom and every baby. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.
Because premature birth is such a complex problem, with multiple causes, March of Dimes has chosen Prematurity Research Centers and partners who can use different tools and methods to examine the factors involved in different ways. Each center’s work informs and amplifies the work the other centers are pursuing.
The other five March of Dimes Prematurity Research Centers are located at (with date of launch):
• Stanford University School of Medicine (2011);
• Ohio Collaborative (2013);
• Washington University in St. Louis (2014);
• University of Pennsylvania Perelman School of Medicine (2014);
• University of Chicago-Northwestern University-Duke University (2015).
# # #
1 Born Too Soon: The Global Action Report on Preterm Birth. (WHO, March of Dimes) 2012.
For more information, please contact:
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
Imperial College London
Head of Communications
+44 (0) 207 594 6704
Research Media Officer – Medicine
+44 (0) 207 594 2409
March of Dimes
Director of Media Relations
+ 1 (914) 997 4613
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13 | Pressemelding
Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43 | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+
Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16 | Pressemelding
HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati